Series B - Aktis Oncology - 2024-09-30 - Crunchbase

Aktis Oncology raised $175000000 on 2024-09-30 in Series B. Search Crunchbase. Start Free Trial ... Summary. Overview. Edit Overview Section. Organization Name . Aktis Oncology . …

CouponFollow Extension

$175000000
OFF

Series B - Aktis Oncology - 2024-09-30 - Crunchbase

4 weeks from now

Aktis Oncology raised $175000000 on 2024-09-30 in Series B. Search Crunchbase. Start Free Trial ... Summary. Overview. Edit Overview Section. Organization Name . Aktis Oncology . …

crunchbase.com

$175
OFF

Aktis Oncology Announces $175 Million Oversubscribed Series B …

4 weeks from now

Oct 1, 2024 · Aktis Oncology also announced that three abstracts, including one oral presentation, have been accepted for presentation at the upcoming EORTC-NCI-AACR Symposium on …

biospace.com

$175
OFF

Brown Rudnick Assists Aktis Oncology In $175M Series B Financing

4 weeks from now

Sep 30, 2024 · Brown Rudnick acted as corporate and transactional counsel for biotech company Aktis Oncology in its oversubscribed and upsized $175 million Series B financing. Aktis …

brownrudnick.com

$175
OFF

Aktis Oncology Announces $175 Million Oversubscribed Series B …

4 weeks from now

BOSTON, Sept. 30, 2024 -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad …

pappas-capital.com

$175
OFF

Radiopharmaceutical Firm Aktis Oncology Raises $175M In Series B ...

4 weeks from now

Oct 1, 2024 · Radiology Business

aktisoncology.com

$175
OFF

Aktis Oncology Unveils $175M Series B Financing To Advance …

4 weeks from now

Mon, Sep 30, 2024, 3:01 PM 1 min read By Karen Roman Aktis Oncology said it raised $175 million in Series B financing, led by RA Capital Management, with RTW Investments and …

yahoo.com

$175
OFF

Aktis Raises $175M To Fuel Radiopharma Drug Development

4 weeks from now

Sep 30, 2024 · Boston-based Aktis Oncology has raised $175 million in fresh funding to advance its pipeline of radiopharmaceutical medicines for cancer. The Series B round, announced by …

biopharmadive.com

$175
OFF

Aktis Oncology Unveils $175M Series B Financing To Advance …

4 weeks from now

Sep 30, 2024 · Sign up for the latest from Aktis Oncology. Email address: Leave this field empty if you're human: Contact Us

aktisoncology.com

$175
OFF

AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED …

4 weeks from now

BOSTON, Sept. 30, 2024 /PRNewswire/ -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha …

epicos.com

$175
OFF

Big Pharma Backers Return For Aktis' $175M Series B

4 weeks from now

Sep 30, 2024 · Having banked $60 million from Eli Lilly in the spring, Aktis Oncology has now closed an upsized $175 million series B that saw the U.S. Big Pharma rejoin a range of big …

fiercebiotech.com

$175
OFF

AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED …

4 weeks from now

BOSTON, September 30, 2024-- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to …

vcaonline.com

$175
OFF

T. Rowe Price Funds Join $175M Series B For Aktis Oncology

4 weeks from now

Oct 1, 2024 · T. Rowe Price Funds Join $175M Series B for Aktis Oncology ... CityBiz

aktisoncology.com

FAQs about Series B - Aktis Oncology - 2024-09-30 - Crunchbase Coupon?

What happened to aktis oncology?

BOSTON, Mass. – September 30, 2024 — Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. ...

Has Aktis Oncology completed a Series A financing?

Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers, completed a $72 million Series A financing. ...

What is aktis oncology?

Aktis Oncology is a clinical stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors. The company’s first of several pipeline programs targets Nectin-4, a tumor-associated antigen found in urothelial and other solid cancers. ...

When will aktis oncology present a presentation?

Aktis Oncology also announced that three abstracts, including one oral presentation, have been accepted for presentation at the upcoming in Barcelona, Spain, October 23-25, 2024. ...

Who will join the aktis Oncology board of directors?

In conjunction with the financing, Andrew Levin, MD, PhD, Partner and Managing Director at RA Capital Management, will join the Aktis Oncology Board of Directors. Lauren Lee, PhD, from RTW Investments, and Vish Sridharan, MD, from Janus Henderson Investors, will join as Observers to the Board of Directors. ...

Who backed aktis?

The Series B round, announced by Aktis Monday, was led by RA Capital Management and co-led by RTW Investments and Janus Henderson Investors. It also drew in pharmas that had previously backed Aktis, namely Bristol Myers Squibb, Eli Lilly and Merck & Co., the latter of which invested via its MRL Ventures Fund. ...